Track topics on Twitter Track topics that are important to you
The U.S. Patent and Trademark Office granted U.S. Patent No. 9,737,496 B2 to Acucela for method of use of its Stargardt disease treatment emixustat hydrochloride or a “broad number of related compounds,” according to a company press release.Emixustat was granted orphan drug designation in January for the treatment of Stargardt disease, which affects fewer than 40,000 patients in the United States.NEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...